Navigation Links
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Date:1/8/2008

tment period. The primary efficacy endpoint of the trial will be the increase from baseline in spontaneous bowel movements per week (SBMs per week). Additional endpoints include monitoring of other symptoms of OBD, which will include the Patient Assessment of Constipation Symptoms (PAC-SYM) outcomes tool, and other quality of life measures. Maintenance of opioid analgesic effect will be assessed by measuring changes from baseline in mean daily opioid requirements and daily pain scores. Safety and tolerability will be assessed and pharmacokinetics of the drug will be evaluated. The trial will be conducted in approximately 50 centers in North America and Europe.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to reduce penetration of drugs across the blood-brain barrier, an important potential advance for NKTR-118 and possibly many other small molecule therapies.

The peripheral opioid antagonist NKTR-118 targets opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Currently, there are no specific drugs approved or specifically indicated to treat OBD or OIC. NKTR-118 has been studied in two Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of single and repeated dose administration of the drug.

In a proof-of-principle Phase 1 trial, single oral doses of NKTR-118 antagonized morphine-induced delay in gastrointestinal transit time demonstrating the potential of the drug to relieve constipation caused by opioid treatment. This effect was seen to increase in a dose-dependent fas
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
11. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  ResMed (NYSE: RMD ) ... Exchange program, a comprehensive suite of software and ... other health care providers. ResMed ... patient information. It integrates valuable sleep and respiratory ... management platforms with customers, in-house or third-party electronic ...
(Date:10/20/2014)... 20, 2014   BioNano Genomics announced today achievement ... to collect human data at 30X depth, sufficient for a ... new capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s ... be showcasing this advancement at the American Society for ...
(Date:10/20/2014)...   Taiho Oncology, Inc. , a subsidiary ... ), announced that the U.S. Food and ... TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an ... treatment of refractory metastatic colorectal cancer (mCRC), and ... submission to the FDA. According to the American ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... 19, 2011 Enhanced Equity Fund (EEF), a healthcare-focused ... investment in MedTest DX, Inc. (MedTest), a medical diagnostic ... to purchase the chemistry diagnostics business from Polymedco, Inc. ... of EEF.  Terms were not disclosed. "EEF ...
... 2011 Wound Management Technologies, Inc., (OTCQB: WNDM | ... the publication of an interview of its President Deborah ... of interviews with CEOs and CFOs of publicly traded ... conducted by Lynn Fosse, Senior Editor, CEOCFOInterviews.com include why ...
Cached Medicine Technology:Enhanced Equity Fund and James White Invest in MedTest DX, Inc. 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 3
(Date:10/20/2014)... 2014 The Advocator Group, LLC ... the American Foundation for Suicide Prevention’s (AFSP) Out of ... a not-for-profit organization that hosts hundreds of community walks ... events are used to help understand and prevent suicide ... relationships as well. , The Advocator Group shares ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
... State University College of Nursing & Healthcare ... national Healthcare Innovation Challenge(R) ( http://healthcare.innovationchallenge.com ) in ... a firm that helps organizations run idea competitions. ... January 20 to May 1, 2009, features competition ...
... health care highly as part of efforts to stem ... reforming health care as one of the top priorities ... national survey conducted by researchers from the Kaiser Family ... Americans rank helping the newly unemployed afford health insurance ...
... reimburses patients and physicians who have been shortchanged ... American Medical Association (AMA), along with the Medical Society ... State Medical Association, claims victory with the settlement agreement ... The $350 million settlement marks the largest monetary settlement ...
... 15 The $800 million settlement that Eli,Lilly and Company ... settle civil False Claims,Act charges related to allegedly false or ... traced to the courageous stands taken by,employee whistleblowers, according to ... The company,s settlement with the federal government, which also ...
... The Procter & Gamble,Company (NYSE: PG ... -- Mariano Martin, (56), global customer ... 33 years of service. He will step,down from his ... focus on working,closely with his successor to ensure a ...
... 15 In a lawsuit pending in Wayne County,Circuit ... OmniCare, a,once-large HMO servicing Medicaid recipients, several major Detroit ... claim for $75 Million in,damages from United American Healthcare, ... In their filing, the Provider Creditors ...
Cached Medicine News:Health News:Arizona State University Nursing and Idea Crossing Partner to Conduct First National Healthcare Innovation Challenge 2Health News:Health provisions among public's top priorities for economic stimulus 2Health News:Health provisions among public's top priorities for economic stimulus 3Health News:Health provisions among public's top priorities for economic stimulus 4Health News:Health provisions among public's top priorities for economic stimulus 5Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2Health News:Whistleblowers' Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy 2Health News:Procter & Gamble Announces Organizational Changes 2Health News:Detroit Area Hospitals Seek $75 Million from United American HealthCare Arising out of its Management of the Liquidated OmniCare HMO 2
... Fast - Powerful g-Force for Fast and Optimal ... rpm (18,000 x g) Ideal for pelleting of ... Fits on crowded bench or in a cold ... aerosol-tight, autoclavable fixed-angle rotor Quiet operation ...
... EXD explosion-proof laboratory floor model centrifuge meets ... EXD is suitable for use in Class ... "atmospheres containing gasoline, petroleum, naphtha, benzol, lacquer, ... these specifications is so strict that the ...
Inquire...
... The XCell line of mini-cells ... simple sturdy and convenient. The tradition ... Mini-Cell. The incorporation of a gel ... rear wedge used on earlier models ...
Medicine Products: